The key receptors targeted by ImmunOs´ immunotherapeutics are called LILRB (leukocyte immunoglobulin-like) receptors. LILRB receptors control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Some transduce a negative signal to immune cells such as macrophages, MDSCs, T cells, and NK cells and thereby inhibit stimulation of an immune response. Tumors exploit this mechanism, e.g. by expressing inhibitory LILRB receptors to suppress the immune system. Therefore, LILRB receptors are important targets in cancer immunotherapy.

Background on ImmunOs´ multi-targeting approach for remodeling the tumor microenvironment